January 29, 2016

Marijuana And Cannabinoids: A Neuroscience Research Summit

January 29, 2016
neuroscience marijuana
neuroscience marijuana
(image via McGill.ca)

This is a notice of a conference of significance in the medical cannabis field. The Research Summit will be held on March 22-23 at the Natcher Conference Center on the National Institutes of Health campus in Bethesda, Maryland.

After viewing the advertisement for the event I question the premise, as the cannabinoid system itself has no adverse effects; the phrasing of the event’s summary implies a bias toward finding harm, a charge that Dr. Sanjay Gupta and other have levied against the NIH and NIDA for some time.

The discussions will include a Michigan contingent, as Dr. Christine Rabinak from Wayne State University will participate in the section reserved for Therapeutic Potential: Epilepsy, Multiple Sclerosis, Pain, PTSD/Anxiety. 

She was the lead author on a paper published in 2013 regarding marijuana use and PTSD.


Marijuana and Cannabinoids: A Neuroscience Research Summit is being convened by the National Institutes of Health (NIH), which will focus on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of the cannabinoid system will be discussed. The goal of this summit is to ensure evidence-based information is available to inform practice and policy, particularly important at this time given the rapidly shifting landscape regarding the recreational and medicinal use of marijuana.

The meeting is being sponsored by several NIH Institutes and Centers: the National Institute on Drug Abuse(NIDA); the National Institute on Alcohol Abuse and Alcoholism (NIAAA); the National Center for Complementary and Integrative Health (NCCIH); the National Institute of Mental Health (NIMH); and theNational Institute of Neurological Disorders and Stroke (NINDS).



Understanding the Endocannabinoid System

Benjamin Cravatt, Ph.D.
The Scripps Research InstituteKen Mackie, M.D.
Indiana UniversityDaniele Piomelli, Ph.D., Pharm.D.
University of California, Irvine

Brain Development and Function

Susan Tapert, Ph.D.
University of California, San DiegoKent Hutchison, Ph.D.
University of Colorado BoulderMadeline Meier, Ph.D.
Arizona State University

Psychosis, Addiction, and Alcohol Interactions

Anne Eden Evins, M.D., M.P.H.
Massachusetts General HospitalAlan Budney, Ph.D.
Geisel School of Medicine at DartmouthLarry Parsons, Ph.D.
The Scripps Research Institute

Psychomotor Performance and Detection

Marilyn Huestis, Ph.D.
National Institute on Drug Abuse

Therapeutic Potential: Epilepsy, Multiple Sclerosis, Pain, PTSD/Anxiety

Ivan Soltesz, Ph.D.
Stanford UniversityAmy Brooks-Kayal, M.D.
Children’s Hospital ColoradoDavid Gloss, M.D., M.P.H.
Charleston Area Medical CenterAndrea G. Hohmann, Ph.D.
Indiana University

Barth Wilsey, M.D.
University of California, San Diego

Cecilia Hillard, Ph.D.
Medical College of Wisconsin

Christine Rabinak, Ph.D.
Wayne State University

Policy-Related Research

Rosalie Liccardo Pacula, Ph.D.
RAND CorporationMark Kleiman, Ph.D., M.P.P.
NYU Marron Institute of Urban Management

Please visit the website for detailed security and location information.


Source: The Compassion Chronicles


Share on facebook
Share on twitter
Share on pinterest
Share on reddit
Recent & Related Posts
Recent & Related Posts